Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.

Author: ChiaYen Lin, RoskosLorin K, WangBing, YanLi

Paper Details 
Original Abstract of the Article :
INTRODUCTION: Benralizumab, an interleukin-5 receptor alpha-directed cytolytic anti-eosinophil monoclonal antibody, was recently approved as add-on maintenance treatment for patients aged 12 years and older with uncontrolled asthma with eosinophilic inflammation. METHODS: Pharmacokinetic (PK) data ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584252/

データ提供:米国国立医学図書館(NLM)

Benralizumab: Understanding its Pharmacokinetics in Asthma

Benralizumab, a monoclonal antibody used to treat asthma with eosinophilic inflammation, has shown promising results in clinical trials. This study delves into the pharmacokinetics (PK) of benralizumab, exploring how the drug is absorbed, distributed, metabolized, and eliminated from the body. The study analyzes data from nine clinical trials, pooling data from both adult and adolescent patients with asthma. The aim is to understand the factors that influence the PK of benralizumab and optimize its use in treating asthma.

Benralizumab's Pharmacokinetics: A Deeper Dive

This study provides valuable insights into the PK of benralizumab. The analysis demonstrates that the PK of benralizumab is dose-proportional across a wide range of doses and is influenced by factors like body weight and the presence of anti-drug antibodies (ADAs). These findings are crucial for understanding how benralizumab is processed by the body and ensuring its safe and effective use in treating asthma.

Tailoring Treatment: Optimizing Benralizumab Therapy

This research underscores the importance of considering patient-specific factors, such as body weight and ADA status, when determining the appropriate dosage of benralizumab. The study's findings contribute to a more personalized approach to asthma treatment, optimizing the use of benralizumab to achieve the best possible outcomes.

Dr. Camel's Conclusion

This study provides a detailed analysis of the PK of benralizumab, shedding light on the factors that influence its absorption, distribution, metabolism, and elimination. The research highlights the importance of considering patient-specific factors, such as body weight and ADA status, when determining the appropriate dosage of benralizumab. This study contributes to a more nuanced understanding of benralizumab and its application in treating asthma, emphasizing the importance of a personalized approach to medication management.

Date :
  1. Date Completed 2020-08-24
  2. Date Revised 2021-05-11
Further Info :

Pubmed ID

30854591

DOI: Digital Object Identifier

PMC6584252

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.